SRR650140
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- OXIDATIVE_PHOSPHORYLATION+0.440
- MYC_TARGETS_V1+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- DNA_REPAIR+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
- INTERFERON_GAMMA_RESPONSE+0.110
- GLYCOLYSIS+0.090
- MTORC1_SIGNALING+0.090
- UNFOLDED_PROTEIN_RESPONSE+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- HEDGEHOG_SIGNALING-0.520
- ANGIOGENESIS-0.510
- ALLOGRAFT_REJECTION-0.430
- MYOGENESIS-0.380
- UV_RESPONSE_DN-0.380
- INFLAMMATORY_RESPONSE-0.370
- KRAS_SIGNALING_UP-0.370
- WNT_BETA_CATENIN_SIGNALING-0.370
- IL2_STAT5_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0076_T1_RNA | — | B | 0.842 |
| 2 | 9da01737-be8f-4af5-9f8f-47bb892b6339 | — | — | 0.838 |
| 3 | SRR1797241 | — | cohortSC | 0.820 |
| 4 | TCGA-E7-A5KF-01A-11R-A28M-07 | — | — | 0.817 |
| 5 | SRR493939 | — | cohortA1 | 0.809 |
| 6 | MBCProject_4278_T3_RNA | — | C | 0.805 |
| 7 | SRR35579830 | — | B | 0.805 |
| 8 | SRR2016966 | — | — | 0.804 |
| 9 | R28 | — | — | 0.804 |
| 10 | SRR33346955 | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |